Jump to Main Content
- Chilakamarthi, Ushasri; Koteshwar, Devulapally; Jinka, Sudhakar; Vamsi Krishna, Narra; Sridharan, Kathyayani; Nagesh, Narayana; Giribabu, Lingamallu
- Biochemistry 2018 v.57 no.46 pp. 6514-6527
- DNA; adverse effects; antineoplastic agents; apoptosis; binding capacity; cell cycle checkpoints; cell lines; cell proliferation; cytotoxicity; drug therapy; fluorescence; irradiation; melting; neoplasm cells; neoplasms; porphyrins; spectroscopy; tissues
- ... Porphyrins are well-known anticancer agents because of their high binding affinity for G-quadruplex DNA and excellent photophysical properties. Several studies carried out using TMPyP4 established it as an efficient chemotherapeutic and a photodynamic therapeutic (PDT) agent, but its use as a lead molecule has been restricted because of its high level of binding to double-stranded DNA (dsDNA), whi ...
- Surnar, Bapurao; Kolishetti, Nagesh; Basu, Uttara; Ahmad, Anis; Goka, Erik; Marples, Brian; Kolb, David; Lippman, Marc E.; Dhar, Shanta
- Biochemistry 2018 v.57 no.46 pp. 6500-6513
- DNA; DNA damage; adverse effects; antineoplastic activity; aspirin; cisplatin; drug therapy; in vitro studies; models; nausea; nephrotoxicity; neurotoxicity; patients; urinary bladder neoplasms
- ... Cisplatin is a major chemotherapeutic that continues to have a significant impact in the treatment of more than 50% of all cancers. Since its Food and Drug Administration approval in 1978 for the treatment of advanced ovarian and bladder cancer, this chemotherapeutic has made significant strides and its application has been extended to a large variety of other cancers. However, the vast majority o ...